Annexon (ANNX) Non-Current Assets (2019 - 2026)
Annexon (ANNX) posted quarterly Non-Current Assets of $34.6 million for Q1 2026, down 0.7% year-over-year from $34.9 million in Q1 2025, and down 2.14% quarter-over-quarter from $35.4 million in Q4 2025.
Annexon (ANNX) Non-Current Assets (2019 - 2026) Analysis & Trends
Annexon's Non-Current Assets history runs 8 years deep, the most recent figure standing at $34.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 0.7% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $140.3 million (up 3.85% YoY), while the FY2025 annual figure was $35.4 million, up 5.27% from the prior year.
- Non-Current Assets for Q1 2026 stood at $34.6 million, down from $35.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $39.3 million in Q2 2022, with the low at $32.1 million in Q2 2024.
- The 5-year median for Non-Current Assets is $34.9 million (2025), against an average of $35.4 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 1415.03% in 2022, then fell 9.86% in 2023.
- Annexon's Non-Current Assets stood at $37.0 million in 2022, then declined by 8.61% to $33.8 million in 2023, then retreated by 0.6% to $33.6 million in 2024, then increased by 5.27% to $35.4 million in 2025, then slipped by 2.14% to $34.6 million in 2026.
- Business Quant data shows ANNX's Non-Current Assets at $34.6 million in Q1 2026, $35.4 million in Q4 2025, and $36.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 33.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.31 Mn |
| Mar 31, 2026 | 34.62 Mn |
| Dec 31, 2025 | 35.38 Mn |
| Sep 30, 2025 | 36.32 Mn |
| Jun 30, 2025 | 33.95 Mn |
| Mar 31, 2025 | 34.87 Mn |
| Dec 31, 2024 | 33.61 Mn |
| Sep 30, 2024 | 34.48 Mn |
| Jun 30, 2024 | 32.12 Mn |
| Mar 31, 2024 | 33.33 Mn |
| Dec 31, 2023 | 33.81 Mn |
| Sep 30, 2023 | 34.65 Mn |
| Jun 30, 2023 | 35.45 Mn |
| Mar 31, 2023 | 36.24 Mn |
| Dec 31, 2022 | 37.00 Mn |
| Sep 30, 2022 | 37.95 Mn |
| Jun 30, 2022 | 39.33 Mn |
| Mar 31, 2022 | 39.32 Mn |
| Dec 31, 2021 | 39.35 Mn |
| Sep 30, 2021 | 34.66 Mn |